瘢痕、血管瘤和肢体淋巴水肿是整形外科领域的常见病和难治性疾病，具有较高的发病率，严重影响患者的身心健康。因此，进一步明确疾病的发病机制、提高疾病的诊断效率和治疗技术的创新一直是这一领域关注的重点。本课题组在相关领域的研究中取得以下进展：①阐述了病理性干细胞、耐药性和生长分化因子-9（GDF9）差异表达在瘢痕疙瘩中的发病机制；②建立了低浓度化学药物瘢痕疙瘩治疗体系，显著提高治愈率和降低复发率；③建立了组织工程皮肤促进创面愈合、减少瘢痕形成的方法；④建立了婴幼儿血管瘤诊断与治疗体系；⑤建立了葡萄酒色斑的临床分类；⑥建立了静脉畸形的诊断和治疗体系；⑦建立了动静脉畸形的诊断和治疗体系；⑧初步阐明了炎性淋巴管生长的分子机制；⑨建立了肢体淋巴水肿动态核磁共振淋巴造影诊断体系；⑩开发了淋巴水肿治疗中药。

Scar, vascular anomalies and lymphedema are the common diseases that are difficult to treat, which severely affect patients´ psychological and physical fitness. Therefore, further defining the disease mechanism and improving the diagnosis and therapeutic efficiency are the important topics of this area. In this project, our group has: ①revealed the role of keloid stem cells, drug resistance and GDF-9 differentiation in keloid development; ②established low dose chemotherapy of keloid with increased cure rate and reduced recurrence rate; ③established engineered epidermis to treat wound bed to inhibit scar formation; ④established diagnosis and therapy system in infantile hemangioma; ⑤established clinical classification of port wine stains; ⑥established diagnosis and therapy of venous malformations; ⑦established diagnosis and therapy methods for arteriovenous malformations; ⑧preliminarily defined the molecular mechanism of lymphedema; ⑨established MRI diagnosis for lymphedema; ⑩development of specialized traditional Chinese medicine for lymphedema.